霍奇金淋巴瘤的过继性T细胞治疗
综述讨论过继性免疫治疗在经典型霍奇金淋巴瘤(cHL)中的临床试验格局。EBV特异性细胞毒性T淋巴细胞和CD30 CAR T细胞在早期临床试验中显示显著临床反应,靶向免疫抑制微环境的CD19和CD123 CAR T细胞亦有研究。文章展望当前挑战与改进CAR T细胞治疗开发的新策略。
要点
- EBV特异性CTL和CD30 CAR T在cHL早期试验显示显著临床反应。
- CD19和CD123 CAR T靶向cHL免疫抑制肿瘤微环境已被研究。
- cHL过继性免疫治疗发展速度不及B细胞非霍奇金淋巴瘤CAR T。
核心结论
- 过继性T细胞治疗在cHL早期临床试验中显示显著临床反应,但发展速度不及B细胞非霍奇金淋巴瘤的CAR T细胞治疗。
研究设计与样本
- 综述讨论cHL过继性免疫治疗的临床试验格局,涵盖EBV特异性CTL、CD30 CAR T、CD19 CAR T和CD123 CAR T。
主要发现
- EBV特异性细胞毒性T淋巴细胞和CD30 CAR T细胞在cHL患者早期临床试验中显示显著临床反应。
- 靶向cHL免疫抑制肿瘤微环境的CD19和CD123 CAR T细胞也已被研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although CAR T-cell therapy is US Food and Drug Administration-approved for B-cell non-Hodgkin lymphomas, the development of adoptive immunotherapy for the treatment of classic Hodgkin lymphoma (cHL) has not accelerated at a similar pace. Adoptive T-cell therapy with Epstein-Barr virus-specific cytotoxic T lymphocytes and CD30 CAR T cells have demonstrated significant clinical responses in early clinical trials of patients with cHL. Additionally, CD19 and CD123 CAR T cells that target the immunosuppressive tumor microenvironment in cHL have also been investigated. Here we discuss the landscape of clinical trials of adoptive immunotherapy for patients with cHL with a view toward current challenges and novel strategies to improve the development of CAR T-cell therapy for cHL.
引用
- Ho C, Ruella M, Levine BL, et al. Adoptive T-cell therapy for Hodgkin lymphoma. Blood Adv. 2021. PMID: 34610100. doi:10.1182/bloodadvances.2021005304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。